{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T14:58:17Z","timestamp":1790780297541,"version":"4.1.0"},"reference-count":116,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2016,10,24]],"date-time":"2016-10-24T00:00:00Z","timestamp":1477267200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2017,4]]},"DOI":"10.1007\/s00415-016-8308-8","type":"journal-article","created":{"date-parts":[[2016,10,24]],"date-time":"2016-10-24T01:51:14Z","timestamp":1477273874000},"page":"804-813","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":46,"title":["Alzheimer\u2019s disease in people with Down\u2019s syndrome: the prospects for and the challenges of developing preventative treatments"],"prefix":"10.1007","volume":"264","author":[{"given":"Paula","family":"Castro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahid","family":"Zaman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4107-130X","authenticated-orcid":false,"given":"Anthony","family":"Holland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,10,24]]},"reference":[{"key":"8308_CR1","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1007\/BF02876635","volume":"122","author":"F Struwe","year":"1929","unstructured":"Struwe F (1929) Histopathologische Untersuchungen \u00fcber entstehung und wesen der senilen Plaques. Zeitschrift f\u00fcr die gesamte Neurologie und Psychiatrie 122:291\u2013307. doi: 10.1007\/BF02876635","journal-title":"Zeitschrift f\u00fcr die gesamte Neurologie und Psychiatrie"},{"key":"8308_CR2","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1017\/S0033291700009120","volume":"16","author":"C Oliver","year":"1986","unstructured":"Oliver C, Holland AJ (1986) Down\u2019s syndrome and Alzheimer\u2019s disease: a review. Psychol Med 16:307\u2013322. doi: 10.1017\/S0033291700009120","journal-title":"Psychol Med"},{"key":"8308_CR3","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1111\/j.1469-8749.2004.tb00483.x","volume":"46","author":"AH Bittles","year":"2004","unstructured":"Bittles AH, Glasson EJ (2004) Clinical, social, and ethical implications of changing life expectancy in Down syndrome. Dev Med Child Neurol 46:282\u2013286. doi: 10.1111\/j.1469-8749.2004.tb00483.x","journal-title":"Dev Med Child Neurol"},{"key":"8308_CR4","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1111\/j.1741-1130.2010.00249.x","volume":"7","author":"J Torr","year":"2010","unstructured":"Torr J, Strydom A, Patti P, Jokinen N (2010) Aging in Down syndrome: morbidity and mortality. J Policy Pract Intellect Disabil 7:70\u201381. doi: 10.1111\/j.1741-1130.2010.00249.x","journal-title":"J Policy Pract Intellect Disabil"},{"key":"8308_CR5","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1111\/j.1365-2788.2006.00842.x","volume":"50","author":"A Coppus","year":"2006","unstructured":"Coppus A, Evenhuis H, Verberne GJ, Visser F, Van Gool P, Eikelenboom P, Van Duijin C (2006) Dementia and mortality in persons with Down\u2019s syndrome. J Intell Disabil Res 50:768\u2013777. doi: 10.1111\/j.1365-2788.2006.00842.x","journal-title":"J Intell Disabil Res"},{"key":"8308_CR6","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1001\/archneur.1989.00520440031017","volume":"46","author":"F Lai","year":"1989","unstructured":"Lai F, Williams S (1989) A prospective study of Alzheimer disease in Down syndrome. Arch Neurol 46:849\u2013853. doi: 10.1001\/archneur.1989.00520440031017","journal-title":"Arch Neurol"},{"key":"8308_CR7","first-page":"400","volume":"101","author":"FE Visser","year":"1997","unstructured":"Visser FE, Aldenkamp AP, van Huffelen AC, Kuilman M (1997) Prospective study of the prevalence of Alzheimer-type dementia in institutionalized individuals with Down syndrome. Am J Ment Retard 101:400\u2013412","journal-title":"Am J Ment Retard"},{"key":"8308_CR8","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1192\/bjp.172.6.493","volume":"172","author":"AJ Holland","year":"1998","unstructured":"Holland AJ, Hon J, Huppert FA, Stevens F, Watson P (1998) Population-based study of the prevalence and presentation of dementia in adults with Down\u2019s syndrome. Br J Psychiatry 172:493\u2013498. doi: 10.1192\/bjp.172.6.493","journal-title":"Br J Psychiatry"},{"key":"8308_CR9","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1192\/bjp.180.5.405","volume":"180","author":"N Schupf","year":"2002","unstructured":"Schupf N, Sergievsky GH (2002) Genetic and host factors for dementia in Down\u2019s syndrome. Br J Psychiatry 180:405\u2013410. doi: 10.1192\/bjp.180.5.405","journal-title":"Br J Psychiatry"},{"key":"8308_CR10","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1159\/000007940","volume":"39","author":"Y Sekijima","year":"1998","unstructured":"Sekijima Y, Ikeda S, Tokuda T, Satoh S, Hidaka H, Hidaka E, Ishikawa M, Yanagisawa N (1998) Prevalence of dementia of Alzheimer type and apolipoprotein E phenotypes in aged patients with Down\u2019s syndrome. Eur Neurol 39:234\u2013237. doi: 10.1159\/000007940","journal-title":"Eur Neurol"},{"key":"8308_CR11","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1212\/WNL.53.2.331","volume":"53","author":"F Lai","year":"1999","unstructured":"Lai F, Kamman E, Rebeck GW, Anderson A, Chen Y, Nixon RA (1999) APOE genotype and gender effects on Alzheimer disease in 100 adults with Down syndrome. Neurology 53:331\u2013336. doi: 10.1212\/WNL.53.2.331","journal-title":"Neurology"},{"key":"8308_CR12","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1002\/gps.1545","volume":"21","author":"SL Ball","year":"2006","unstructured":"Ball SL, Holland AJ, Huppert FA, Treppner P, Watson P, Hon J (2006) Personality and behaviour changes mark the early stages of Alzheimer\u2019s disease in adults with Down\u2019s syndrome: findings from a prospective population-based study. Int J Geriatr Psychiatry 21:661\u2013673","journal-title":"Int J Geriatr Psychiatry"},{"key":"8308_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1348\/014466507X230967","volume":"47","author":"SL Ball","year":"2008","unstructured":"Ball SL, Holland AJ, Treppner P, Watson PC, Huppert FA (2008) Executive dysfunction and its association with personality and behaviour changes in the development of Alzheimer\u2019s disease in adults with Down syndrome and mild to moderate learning disabilities. Br J Clin Psychol 47:1\u201329. doi: 10.1348\/014466507X230967","journal-title":"Br J Clin Psychol"},{"key":"8308_CR14","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1016\/j.ridd.2009.01.010","volume":"30","author":"RE Nieuwenhuis-Mark","year":"2009","unstructured":"Nieuwenhuis-Mark RE (2009) Diagnosing Alzheimer\u2019s dementia in Down syndrome: problems and possible solutions. Res Dev Disabil 30:827\u2013838. doi: 10.1016\/j.ridd.2009.01.010","journal-title":"Res Dev Disabil"},{"key":"8308_CR15","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1111\/j.1365-2788.2004.00630.x","volume":"48","author":"SL Ball","year":"2004","unstructured":"Ball SL, Holland AJ, Huppert FA, Treppner P, Watson P, Hon J (2004) The modified CAMDEX informant interview is a valid and reliable tool for use in the diagnosis of dementia in adults with Down\u2019s syndrome. J Intell Disabil Res 48:611\u2013620. doi: 10.1111\/j.1365-2788.2004.00630.x","journal-title":"J Intell Disabil Res"},{"key":"8308_CR16","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1002\/ana.410170310","volume":"17","author":"KE Wisniewski","year":"1985","unstructured":"Wisniewski KE, Wisniewski HM, Wen GY (1985) Occurrence of neuropathological changes and dementia of Alzheimer\u2019s disease in Down\u2019s syndrome. Ann Neurol 17:278\u2013282. doi: 10.1002\/ana.410170310","journal-title":"Ann Neurol"},{"key":"8308_CR17","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/0022-510X(90)90152-D","volume":"99","author":"DMA Mann","year":"1990","unstructured":"Mann DMA, Royston MC, Ravindra CR (1990) Some morphometric observations on the brains of patients with Down\u2019s syndrome: their relationship to age and dementia. J Neurol Sci 99:153\u2013164. doi: 10.1016\/0022-510X(90)90152-D","journal-title":"J Neurol Sci"},{"key":"8308_CR18","doi-asserted-by":"publisher","first-page":"1168","DOI":"10.1002\/gps.502","volume":"16","author":"J Tyrrell","year":"2001","unstructured":"Tyrrell J, Cosgrave M, McCarron M, McPherson J, Calvert J, Kelly A, McLaughlin M, Gill M, Lawlor BA (2001) Dementia in people with Down\u2019s syndrome. Int J Geriat Psychiat 16:1168\u20131174. doi: 10.1002\/gps.502","journal-title":"Int J Geriat Psychiat"},{"key":"8308_CR19","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1111\/j.1468-3148.1998.tb00066.x","volume":"11","author":"L Crayton","year":"1998","unstructured":"Crayton L, Oliver C, Holland A, Bradbury J, Hall S (1998) The neuropsychological assessment of age related cognitive deficits in adults with Down syndrome. J Appl Res Intellect Disab 11:255\u2013272. doi: 10.1111\/j.1468-3148.1998.tb00066.x","journal-title":"J Appl Res Intellect Disab"},{"key":"8308_CR20","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1126\/science.1566067","volume":"256","author":"JA Hardy","year":"1992","unstructured":"Hardy JA, Higgins GA (1992) Alzheimer\u2019s disease\u2014the amyloid cascade hypothesis. Science 256:184\u2013185","journal-title":"Science"},{"key":"8308_CR21","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1097\/00005072-199409000-00003","volume":"53","author":"DJ Selkoe","year":"1994","unstructured":"Selkoe DJ (1994) Alzheimer\u2019s disease: a central role for amyloid. J Neuropathol Exp Neurol 53:438\u2013447","journal-title":"J Neuropathol Exp Neurol"},{"key":"8308_CR22","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/j.jalz.2007.11.008","volume":"4","author":"AD Korczyn","year":"2008","unstructured":"Korczyn AD (2008) The amyloid cascade hypothesis. Alzheimer\u2019s Dement 4:176\u2013178. doi: 10.1016\/j.jalz.2007.11.008","journal-title":"Alzheimer\u2019s Dement"},{"key":"8308_CR23","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1016\/S0166-2236(96)01030-2","volume":"22","author":"J Hardy","year":"1997","unstructured":"Hardy J (1997) Amyloid, the presenilins and Alzheimer\u2019s disease. Trends Neurosci 22:485\u2013486. doi: 10.1016\/S0166-2236(96)01030-2","journal-title":"Trends Neurosci"},{"key":"8308_CR24","first-page":"23","volume":"24","author":"D Goldgaber","year":"1987","unstructured":"Goldgaber D, Lerman MI, Mcbride WO, Saffiotti U, Gajdusek DC (1987) Isolation, characterization, and chromosomal localization of human brain cDNA clones coding for the precursor of the amyloid of brain in Alzheimer\u2019s disease, Down\u2019s syndrome and aging. J Neural Transm S 24:23\u201328","journal-title":"J Neural Transm S"},{"key":"8308_CR25","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1038\/nrn3983","volume":"16","author":"FK Wiseman","year":"2015","unstructured":"Wiseman FK, Al-Janabi T, Hardy J, Karmiloff-Smith A, Nizetic D, Tybulewics VLJ, Fisher EMC, Strydom A (2015) A genetic cause of Alzheimer disease: mechanistic insights from Down syndrome. Nat Rev Neurosci 16:564\u2013574. doi: 10.1038\/nrn3983","journal-title":"Nat Rev Neurosci"},{"key":"8308_CR26","volume-title":"BACE lead target for orchestrated therapy of Alzheimer\u2019s disease","author":"J Varghese","year":"2010","unstructured":"Varghese J (2010) BACE lead target for orchestrated therapy of Alzheimer\u2019s disease. Wiley, Hoboken"},{"key":"8308_CR27","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1001\/archneur.1995.00540280059019","volume":"52","author":"BT Hyman","year":"1995","unstructured":"Hyman BT (1995) Neuropathological changes in Down\u2019s syndrome hippocampal formation. Arch Neurol 52:373\u2013378","journal-title":"Arch Neurol"},{"key":"8308_CR28","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/j.neulet.2010.10.010","volume":"487","author":"A Patel","year":"2011","unstructured":"Patel A, Rees SD, Kelly MA, Bain SC, Barnett AH, Thalitaya D, Prasher VP (2011) Association of variants within APOE, SORL1, RUNX1, BACE1 and ALDH18A1 with dementia in Alzheimer\u2019s disease in subjects with Down syndrome. Neurosci Lett 487:144\u2013148. doi: 10.1016\/j.neulet.2010.10.010","journal-title":"Neurosci Lett"},{"key":"8308_CR29","doi-asserted-by":"crossref","first-page":"2583","DOI":"10.1097\/00001756-199412000-00044","volume":"5","author":"M Royston","year":"1994","unstructured":"Royston M, Mann D, Pickering-Brown S, Owen F, Perry R, Raghavan R, Khin-IMu C, Tyrer S, Day K, Crook R, Hardy J, Roberts GW (1994) Apolipoprotein E \u03b52 allele promotes longevity and protects patients with Down\u2019s syndrome from dementia. Neuroreport 5:2583\u20132585","journal-title":"Neuroreport"},{"key":"8308_CR30","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1155\/2006\/276239","volume":"22","author":"Z Xiang","year":"2006","unstructured":"Xiang Z, Haroutunian V, Ho L, Purohit D, Pasinetti GM (2006) Microglia activation in the brain as inflammatory biomarker of Alzheimer\u2019s disease neuropathology and clinical dementia. Dis Mark 22:95\u2013102. doi: 10.1155\/2006\/276239","journal-title":"Dis Mark"},{"key":"8308_CR31","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/170276","author":"DM Wilcock","year":"2012","unstructured":"Wilcock DM (2012) Neuroinflammation in the aging Down syndrome brain; lessons from Alzheimer\u2019s disease. Curr Gerontol Geriatr Res. doi: 10.1155\/2012\/170276","journal-title":"Curr Gerontol Geriatr Res"},{"key":"8308_CR32","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/j.neurobiolaging.2004.08.005","volume":"26","author":"IT Lott","year":"2005","unstructured":"Lott IT, Head E (2005) Alzheimer disease and Down syndrome: factors in pathogenesis. Neurobiol Aging 26:383\u2013389. doi: 10.1016\/j.neurobiolaging.2004.08.005","journal-title":"Neurobiol Aging"},{"issue":"3","key":"8308_CR33","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1002\/gps.587","volume":"17","author":"VP Prasher","year":"2002","unstructured":"Prasher VP, Huxley A, Haque MS (2002) A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Down syndrome and Alzheimer\u2019s disease\u2014pilot study. Int J Geriatr Psychiatry 17(3):270\u2013278 (PMID: 11921156)","journal-title":"Int J Geriatr Psychiatry"},{"key":"8308_CR34","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1093\/ageing\/afu055","volume":"43","author":"LLF Law","year":"2014","unstructured":"Law LLF, Barnett F, Yau MK, Gray MA (2014) Effects of functional tasks exercise on older adults with cognitive impairment at risk of Alzheimer\u2019s disease: a randomised controlled trial. Age Ageing 43:813\u2013820. doi: 10.1093\/ageing\/afu055","journal-title":"Age Ageing"},{"key":"8308_CR35","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1007\/s40263-015-0230-6","volume":"29","author":"L Rouch","year":"2015","unstructured":"Rouch L, Cestac P, Hanon O, Cool C, Helmer C, Bouhanick B, Chamontin B, Dartiques JF, Vellas B, Andrieu S (2015) Antihypertensive drugs, prevention of cognitive decline and dementia: a systematic review of observational studies, randomized controlled trials and meta-analyses, with discussion of potential mechanisms. CNS Drugs 29:113\u2013130. doi: 10.1007\/s40263-015-0230-6","journal-title":"CNS Drugs"},{"key":"8308_CR36","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1016\/S1474-4422(14)70085-7","volume":"13","author":"AJ Kilian","year":"2014","unstructured":"Kilian AJ, Arnoldussen IAC, Gustafson DR (2014) Adipokines: a link between obesity and dementia? Lancet Neurol 13:913\u2013923. doi: 10.1016\/S1474-4422(14)70085-7","journal-title":"Lancet Neurol"},{"key":"8308_CR37","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1002\/pdi.1839","volume":"31","author":"C Fox","year":"2014","unstructured":"Fox C, Kilvert A (2014) Diabetes and dementia. Pract Diabetes 31:94\u201395","journal-title":"Pract Diabetes"},{"key":"8308_CR38","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003160","author":"B McGuinness","year":"2009","unstructured":"McGuinness B, Craig D, Bullock R, Passmore P (2009) Statins for the prevention of dementia. Cochrane Database Syst Rev. doi: 10.1002\/14651858.CD003160","journal-title":"Cochrane Database Syst Rev"},{"key":"8308_CR39","doi-asserted-by":"publisher","DOI":"10.1186\/1745-6215-15-20","author":"SA Cooper","year":"2014","unstructured":"Cooper SA, Caslake M, Evans J, Hassiotis A, Jahoda A, McConnachie A, Morrison J, Ring H, Starr J, Stiles C, Sullivan F (2014) Toward onset prevention of cognitive decline in adults with Down syndrome (the TOP-COG study): study protocol for a randomized controlled trial. Trials. doi: 10.1186\/1745-6215-15-20","journal-title":"Trials"},{"key":"8308_CR40","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1111\/j.1471-4159.2009.06181.x","volume":"110","author":"J Hardy","year":"2009","unstructured":"Hardy J (2009) The amyloid hypothesis for Alzheimer\u2019s disease: a critical reappraisal. J Neurochem 110:1129\u20131134. doi: 10.1111\/j.1471-4159.2009.06181.x","journal-title":"J Neurochem"},{"key":"8308_CR41","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/369808","author":"C Reitz","year":"2012","unstructured":"Reitz C (2012) Alzheimer\u2019s disease and the amyloid cascade hypothesis: a critical review. Int J Alzheimer\u2019s Dis. doi: 10.1155\/2012\/369808","journal-title":"Int J Alzheimer\u2019s Dis"},{"key":"8308_CR42","doi-asserted-by":"crossref","first-page":"211","DOI":"10.5114\/fn.2014.45562","volume":"52","author":"RA Armstrong","year":"2014","unstructured":"Armstrong RA (2014) A\u00a0critical analysis of the \u2018amyloid cascade hypothesis\u2019. Folia Neuropathol 52:211\u2013225","journal-title":"Folia Neuropathol"},{"key":"8308_CR43","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1186\/s40478-014-0135-5","volume":"2","author":"GP Morris","year":"2014","unstructured":"Morris GP, Clark IA, Vissel B (2014) Inconsistencies and controversies surrounding the amyloid hypothesis of Alzheimer\u2019s disease. Acta Neuropathol 2:135. doi: 10.1186\/s40478-014-0135-5","journal-title":"Acta Neuropathol"},{"key":"8308_CR44","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1186\/s13195-014-0060-7","volume":"6","author":"MS Rafii","year":"2014","unstructured":"Rafii MS (2014) Pro: are we ready to translate Alzheimer\u2019s disease modifying therapies to people with Down syndrome? Alzheimer\u2019s Res Ther 6:60. doi: 10.1186\/s13195-014-0060-7","journal-title":"Alzheimer\u2019s Res Ther"},{"key":"8308_CR45","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.npep.2015.06.008","volume":"52","author":"SH Barage","year":"2015","unstructured":"Barage SH, Sonawane KD (2015) Amyloid cascade hypothesis: pathogenesis and therapeutic strategies in Alzheimer\u2019s disease. Neuropeptides 52:1\u201318. doi: 10.1016\/j.npep.2015.06.008","journal-title":"Neuropeptides"},{"key":"8308_CR46","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1152\/physrev.2001.81.2.741","volume":"81","author":"D Selkoe","year":"2001","unstructured":"Selkoe D (2001) Alzheimer\u2019s disease: genes, proteins, and therapy. Physiol Rev 81:741\u2013766","journal-title":"Physiol Rev"},{"key":"8308_CR47","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1096\/fj.05-5628com","volume":"20","author":"X Sun","year":"2006","unstructured":"Sun X, Tong Y, Qing H, Chen CH, Song W (2006) Increased BACE1 maturation contributes to the pathogenesis of Alzheimer\u2019s disease in Down syndrome. FASEB J 20:1361\u20131368. doi: 10.1096\/fj.05-5628com","journal-title":"FASEB J"},{"key":"8308_CR48","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1016\/S1474-4422(16)00063-6","volume":"15","author":"C Ballard","year":"2016","unstructured":"Ballard C, Mobley W, Hardy J, Williams G, Corbett A (2016) Dementia in Down syndrome. Lancet Neurol 15:622\u2013636. doi: 10.1016\/S1474-4422(16)00063-6","journal-title":"Lancet Neurol"},{"key":"8308_CR49","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.1096\/fj.05-5632com","volume":"20","author":"X Sun","year":"2006","unstructured":"Sun X, He G, Song W (2006) BACE2, as a novel APP theta-secretase, is not responsible for the pathogenesis of Alzheimer\u2019s disease in Down syndrome. FASEB J 20:1369\u20131376. doi: 10.1096\/fj.05-5632com","journal-title":"FASEB J"},{"key":"8308_CR50","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1111\/j.1471-4159.2011.07476.x","volume":"120","author":"AK Ghosh","year":"2012","unstructured":"Ghosh AK, Brindisi M, Tang J (2012) Developing \u03b2-secretase inhibitors for treatment of Alzheimer\u2019s disease. J Neurochem 120:71\u201383. doi: 10.1111\/j.1471-4159.2011.07476.x","journal-title":"J Neurochem"},{"key":"8308_CR51","doi-asserted-by":"publisher","first-page":"10943","DOI":"10.1371\/journal.pone.0010943","volume":"5","author":"WJ Netzer","year":"2010","unstructured":"Netzer WJ, Powell C, Nong Y, Blundell J, Wong L, Duff K, Flajolet M, Greengard P (2010) Lowering \u03b2-amyloid levels rescues learning and memory in a Down syndrome model. PLoS One 5:10943. doi: 10.1371\/journal.pone.0010943","journal-title":"PLoS One"},{"key":"8308_CR52","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1016\/j.bmcl.2014.12.092","volume":"25","author":"JJ Chen","year":"2015","unstructured":"Chen JJ, Qingyian L, Chester Y et al (2015) Development of 2-aminooxazoline 3-azaxanthenes as orally efficacious \u03b2-secretase inhibitors for the potential treatment of Alzheimer\u2019s disease. Bioorg Med Chem Lett 25:767\u2013774. doi: 10.1016\/j.bmcl.2014.12.092","journal-title":"Bioorg Med Chem Lett"},{"key":"8308_CR53","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1111\/j.1750-3639.2005.tb00104.x","volume":"15","author":"TE Golde","year":"2005","unstructured":"Golde TE (2005) The A\u03b2 hypothesis: leading us to rationally-designed therapeutic strategies for the treatment or prevention of Alzheimer disease. Brain Pathol 15:84\u201387. doi: 10.1111\/j.1750-3639.2005.tb00104.x","journal-title":"Brain Pathol"},{"key":"8308_CR54","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1038\/44973","volume":"402","author":"B Strooper De","year":"1999","unstructured":"De Strooper B, Konig G (1999) Alzheimer\u2019s disease: a firm base for drug development. Nature 402:471\u2013472. doi: 10.1038\/44973","journal-title":"Nature"},{"key":"8308_CR55","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1038\/nature09325","volume":"467","author":"G He","year":"2010","unstructured":"He G, Luo W, Li P et al (2010) Gamma-secretase activating protein is a therapeutic target for Alzheimer\u2019s disease. Nature 467:95. doi: 10.1038\/nature09325","journal-title":"Nature"},{"key":"8308_CR56","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1016\/j.bmcl.2012.11.055","volume":"23","author":"H Li","year":"2013","unstructured":"Li H, Qin J, Dhondi P et al (2013) The discovery of fused oxadiazepines as gamma secretase modulators for treatment of Alzheimer\u2019s disease. Bioorg Med Chem Lett 23:466\u2013471. doi: 10.1016\/j.bmcl.2012.11.055","journal-title":"Bioorg Med Chem Lett"},{"key":"8308_CR57","doi-asserted-by":"publisher","first-page":"5805","DOI":"10.1016\/j.bmcl.2014.10.024","volume":"24","author":"AI Velter","year":"2014","unstructured":"Velter AI, Bischoff FP, Berthelot D et al (2014) Anilinotriazoles as potent gamma secretase modulators. Bioorg Med Chem Lett 24:5805\u20135813. doi: 10.1016\/j.bmcl.2014.10.024","journal-title":"Bioorg Med Chem Lett"},{"key":"8308_CR58","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1016\/j.biopsych.2014.06.003","volume":"77","author":"J Chu","year":"2015","unstructured":"Chu J, Li JG, Joshi YB, Giannopoulos PF, Hoffman NE, Madesh M, Pratic\u00f2 D (2015) Gamma secretase-activating protein is a substrate for caspase-3: implications for Alzheimer\u2019s disease. Biol Psychiatry 77:720\u2013728. doi: 10.1016\/j.biopsych.2014.06.003","journal-title":"Biol Psychiatry"},{"key":"8308_CR59","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1002\/ana.24540","volume":"79","author":"J Chu","year":"2016","unstructured":"Chu J, Wisniewski T, Pratic\u00f2 D (2016) GATA1-mediated transcriptional regulation of the \u03b3-secretase activating protein increases A\u03b2 formation in Down syndrome. Ann Neurol 79:138\u2013143. doi: 10.1002\/ana.24540","journal-title":"Ann Neurol"},{"key":"8308_CR60","doi-asserted-by":"crossref","first-page":"3","DOI":"10.4088\/JCP.0706e03","volume":"67","author":"GL Wenk","year":"2006","unstructured":"Wenk GL (2006) Neuropathologic changes in Alzheimer\u2019s disease: potential targets for treatment. J Clin Psychiatry 67:3\u20137","journal-title":"J Clin Psychiatry"},{"key":"8308_CR61","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/S0197-4580(00)00124-X","volume":"21","author":"H Akiyama","year":"2000","unstructured":"Akiyama H, Barger S, Barnum S et al (2000) Inflammation and Alzheimer\u2019s disease. Neurobiol Aging 21:383\u2013421. doi: 10.1016\/S0197-4580(00)00124-X","journal-title":"Neurobiol Aging"},{"key":"8308_CR62","doi-asserted-by":"publisher","first-page":"6254","DOI":"10.1016\/j.bmcl.2013.09.091","volume":"23","author":"F Prati","year":"2013","unstructured":"Prati F, Bartolini M, Simoni E, De Simone A, Pinto A, Andrisano V, Bolognesi ML (2013) Quinones bearing non-steroidal anti-inflammatory fragments as multitarget ligands for Alzheimer\u2019s disease. Bioorg Med Chem Lett 23:6254\u20136258. doi: 10.1016\/j.bmcl.2013.09.091","journal-title":"Bioorg Med Chem Lett"},{"key":"8308_CR63","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1136\/jnnp-2015-310548","volume":"86","author":"W Xu","year":"2015","unstructured":"Xu W (2015) Meta-analysis of modifiable risk factors for Alzheimer\u2019s disease. J Neurol Neurosurg Psychiatry 86:1299\u20131306. doi: 10.1136\/jnnp-2015-310548","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"8308_CR64","doi-asserted-by":"crossref","first-page":"3263","DOI":"10.1097\/00001756-200110290-00024","volume":"12","author":"T Thomas","year":"2001","unstructured":"Thomas T, Nadackal GT, Thomas K (2001) Aspirin and non-steroidal anti-inflammatory drugs inhibit amyloid-\u03b2 aggregation. NeuroReport 12:3263\u20133267","journal-title":"NeuroReport"},{"key":"8308_CR65","doi-asserted-by":"publisher","first-page":"2819","DOI":"10.1001\/jama.289.21.2819","volume":"289","author":"PS Aisen","year":"2003","unstructured":"Aisen PS, Schafer KA, Grundman M, Pfeiffer E, Sano M, Davis KL, Farlow MR, Jin S, Thomas RG, Thal LJ (2003) Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression. J Am Med Assoc 289:2819\u20132826. doi: 10.1001\/jama.289.21.2819","journal-title":"J Am Med Assoc"},{"key":"8308_CR66","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1159\/000285514","volume":"7","author":"AC Cuello","year":"2010","unstructured":"Cuello AC, Ferretti MT, Leon WC, Iulita MF, Melis T, Ducatenzeiler A, Bruno MA, Canneva F (2010) Early-stage inflammation and experimental therapy in transgenic models of the alzheimer-like amyloid pathology. Neurodegener Dis 7:96\u201398. doi: 10.1159\/000285514","journal-title":"Neurodegener Dis"},{"key":"8308_CR67","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1111\/j.1471-4159.2011.07458.x","volume":"120","author":"J Delrieu","year":"2012","unstructured":"Delrieu J, Ousset PJ, Caillaud C, Vellas B (2012) \u2018Clinical trials in Alzheimer\u2019s disease\u2019: immunotherapy approaches. J Neurochem 120:186\u2013193. doi: 10.1111\/j.1471-4159.2011.07458.x","journal-title":"J Neurochem"},{"key":"8308_CR68","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1038\/22124","volume":"400","author":"D Schenk","year":"1999","unstructured":"Schenk D, Barbour R, Dunn W et al (1999) Immunization with amyloid-\u03b2 attenuates Alzheimer disease-like pathology in the PDAPP mouse. Nature 400:173\u2013177. doi: 10.1038\/22124","journal-title":"Nature"},{"key":"8308_CR69","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1212\/01.WNL.0000073623.84147.A8","volume":"61","author":"JM Orgogozo","year":"2003","unstructured":"Orgogozo JM, Gilman S, Dartiques JF et al (2003) Subacute meningoencephalitis in a subset of patients with AD after A\u03b242 immunization. Neurology 61:46\u201354. doi: 10.1212\/01.WNL.0000073623.84147.A8","journal-title":"Neurology"},{"key":"8308_CR70","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1016\/S0896-6273(03)00294-0","volume":"38","author":"C Hock","year":"2003","unstructured":"Hock C, Konietzko U, Streffer JR et al (2003) Antibodies against [beta]-amyloid slow cognitive decline in Alzheimer\u2019s disease. Neuron 38:547\u2013554. doi: 10.1016\/S0896-6273(03)00294-0","journal-title":"Neuron"},{"key":"8308_CR71","first-page":"319","volume":"15","author":"D Lambracht-Washington","year":"2013","unstructured":"Lambracht-Washington D, Rosenberg RN (2013) Advances in the development of vaccines for Alzheimer\u2019s disease. Discov Med 15:319\u2013326","journal-title":"Discov Med"},{"key":"8308_CR72","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1007\/s12603-009-0070-5","volume":"13","author":"A Schneeberger","year":"2009","unstructured":"Schneeberger A, Mandler M, Otawa O, Zauner W, Mattner F, Schmidt W (2009) Development of Affitope vaccines for Alzheimer\u2019s disease (AD)\u2014from concept to clinical testing. Aging 13:264\u2013267. doi: 10.1007\/s12603-009-0070-5","journal-title":"Aging"},{"key":"8308_CR73","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1016\/S1474-4422(12)70140-0","volume":"11","author":"B Winblad","year":"2012","unstructured":"Winblad B, Andreasen N, Minthon L et al (2012) Safety, tolerability, and antibody response of active A\u03b2 immunotherapy with CAD106 in patients with Alzheimer\u2019s disease: randomised, double-blind, placebo-controlled, first-in-human study. Lancet Neurol 11:597\u2013604. doi: 10.1016\/S1474-4422(12)70140-0","journal-title":"Lancet Neurol"},{"key":"8308_CR74","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0152471","author":"PV Belichenko","year":"2016","unstructured":"Belichenko PV, Madani R, Rey-Bellet L et al (2016) An anti-\u03b2-amyloid vaccine for treating cognitive deficits in a mouse model of down syndrome. PLoS One. doi: 10.1371\/journal.pone.0152471","journal-title":"PLoS One"},{"key":"8308_CR75","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1001\/archneurol.2012.90","volume":"69","author":"K Blennow","year":"2012","unstructured":"Blennow K, Zetterberg H, Rinne JO, Salloway S, Wei J, Black R, Grundman M, Liu E (2012) Effect of immunotherapy with bapineuzumab on cerebrospinal fluid biomarker levels in patients with mild to moderate Alzheimer disease. Arch Neurol 69:1002\u20131010. doi: 10.1001\/archneurol.2012.90","journal-title":"Arch Neurol"},{"key":"8308_CR76","doi-asserted-by":"publisher","first-page":"49","DOI":"10.3233\/JAD-2011-110977","volume":"28","author":"B Bohrmann","year":"2012","unstructured":"Bohrmann B, Baumann K, Benz J et al (2012) Gantenerumab: a novel human anti-A\u03b2 antibody demonstrates sustained cerebral amyloid-\u03b2 binding and elicits cell-mediated removal of human amyloid-\u03b2. J Alzheimers Dis 28:49\u201369. doi: 10.3233\/JAD-2011-110977","journal-title":"J Alzheimers Dis"},{"key":"8308_CR77","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/j.jalz.2011.09.224","volume":"8","author":"M Farlow","year":"2012","unstructured":"Farlow M, Arnold SE, Van Dyck CH et al (2012) Safety and biomarker effects of solanezumab in patients with\u00a0Alzheimer\u2019s disease. Alzheimers Dement 8:261\u2013271. doi: 10.1016\/j.jalz.2011.09.224","journal-title":"Alzheimers Dement"},{"key":"8308_CR78","doi-asserted-by":"publisher","first-page":"1975","DOI":"10.1002\/elps.201100660","volume":"33","author":"G Shayan","year":"2012","unstructured":"Shayan G, Adamiak B, Relkin NR, Lee KH (2012) Longitudinal analysis of novel Alzheimer\u2019s disease proteomic cerebrospinal fluid biomarkers during intravenous immunoglobulin therapy. Electrophoresis 33:1975\u20131979. doi: 10.1002\/elps.201100660","journal-title":"Electrophoresis"},{"key":"8308_CR79","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1016\/j.jalz.2012.05.1606","volume":"8","author":"N Relkin","year":"2012","unstructured":"Relkin N, Bettger L, Tsakanikas D, Ravdin L (2012) Three-year follow-up on the IVIg for Alzheimer\u2019s phase II study. Alzheimers Dement 8:589. doi: 10.1016\/j.jalz.2012.05.1606","journal-title":"Alzheimers Dement"},{"key":"8308_CR80","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/S1474-4422(13)70014-0","volume":"12","author":"R Dodel","year":"2013","unstructured":"Dodel R, Rominger A, Bartenstein P et al (2013) Intravenous immunoglobulin for treatment of mild-to-moderate Alzheimer\u2019s disease: a phase 2, randomised, double-blind, placebo-controlled, dose-finding trial. Lancet Neurol 12:233\u2013243. doi: 10.1016\/S1474-4422(13)70014-0","journal-title":"Lancet Neurol"},{"key":"8308_CR81","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1038\/nature19323","volume":"537","author":"J Sevigny","year":"2016","unstructured":"Sevigny J, Chiao P, Bussi\u00e8re T et al (2016) The antibody aducanumab reduces A\u03b2 plaques in Alzheimer\u2019s disease. Nature 537:50\u201356. doi: 10.1038\/nature19323","journal-title":"Nature"},{"key":"8308_CR82","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1016\/j.neuron.2013.12.003","volume":"80","author":"CR Jack","year":"2013","unstructured":"Jack CR, Holtzman DM (2013) Biomarker modelling of Alzheimer\u2019s disease. Neuron 80:1347\u20131358. doi: 10.1016\/j.neuron.2013.12.003","journal-title":"Neuron"},{"key":"8308_CR83","doi-asserted-by":"publisher","DOI":"10.3389\/fnbeh.2015.00239","author":"MS Rafii","year":"2015","unstructured":"Rafii MS, Wishnek H, Brewer JB, Donohue MC, Ness S, Mobley WC, Aisen PS, Rissman RA (2015) The Down syndrome biomarker initiative (DSBI) pilot: proof of concept for deep phenotyping of Alzheimer\u2019s disease biomarkers in Down syndrome. Front Behav Neurosci. doi: 10.3389\/fnbeh.2015.00239","journal-title":"Front Behav Neurosci"},{"key":"8308_CR84","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1038\/nm0896-864","volume":"2","author":"D Scheuner","year":"1996","unstructured":"Scheuner D, Eckman C, Jensen M et al (1996) Secreted amyloid beta-protein similar to that in the senile plaques of Alzheimer\u2019s disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer\u2019s disease. Nat Med 2:864\u2013870. doi: 10.1038\/nm0896-864","journal-title":"Nat Med"},{"key":"8308_CR85","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.1001\/jama.283.12.1571","volume":"283","author":"J Naslund","year":"2000","unstructured":"Naslund J, Haroutunian V, Mohs R, Davis KL, Davies P, Greengard P, Buxbaum JD (2000) Correlation between elevated levels of amyloid B-peptide in the brain and cognitive decline. JAMA 283:1571\u20131577. doi: 10.1001\/jama.283.12.1571","journal-title":"JAMA"},{"key":"8308_CR86","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/S0304-3940(01)01657-3","volume":"301","author":"N Schupf","year":"2001","unstructured":"Schupf N, Patel B, Silverman W, Zigman WB, Zhong N, Tycko B, Mehta D, Mayeux R (2001) Elevated plasma amyloid \u03b2-peptide 1\u201342 and onset of dementia in adults with Down syndrome. Neurosci Lett 301:199\u2013203. doi: 10.1016\/S0304-3940(01)01657-3","journal-title":"Neurosci Lett"},{"key":"8308_CR87","doi-asserted-by":"publisher","first-page":"1639","DOI":"10.1212\/WNL.0b013e3181fb448b","volume":"75","author":"N Schupf","year":"2010","unstructured":"Schupf N, Zigman WB, Tang MX, Pang D, Mayeux R, Mehta PD, Silverman W (2010) Change in plasma A\u03b2 peptides and onset of dementia in adults with Down syndrome. Neurology 75:1639\u20131644. doi: 10.1212\/WNL.0b013e3181fb448b","journal-title":"Neurology"},{"key":"8308_CR88","doi-asserted-by":"publisher","first-page":"1988","DOI":"10.1016\/j.neurobiolaging.2011.08.007","volume":"33","author":"AMW Coppus","year":"2012","unstructured":"Coppus AMW, Schuur M, Vergeer J, Janssens AC, Oostra BA, Verbeek MM, Van Duijn CM (2012) Plasma \u03b2 amyloid and the risk of Alzheimer\u2019s disease in Down syndrome. Neurobiol Aging 33:1988\u20131994. doi: 10.1016\/j.neurobiolaging.2011.08.007","journal-title":"Neurobiol Aging"},{"key":"8308_CR89","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1038\/mp.2008.84","volume":"15","author":"P Lewczuk","year":"2008","unstructured":"Lewczuk P, Kamrowski-Kruck H, Peters O et al (2008) Soluble amyloid precursor proteins in the cerebrospinal fluid as novel potential biomarkers of Alzheimer\u2019s disease: a multicentre study. Mol Psychiatry 15:138. doi: 10.1038\/mp.2008.84","journal-title":"Mol Psychiatry"},{"key":"8308_CR90","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1111\/j.1749-6632.2009.04944.x","volume":"1180","author":"N Mattsson","year":"2009","unstructured":"Mattsson N, Blennow K, Zetterberg H (2009) CSF biomarkers. Ann N Y Acad Sci 1180:28\u201335. doi: 10.1111\/j.1749-6632.2009.04944.x","journal-title":"Ann N Y Acad Sci"},{"key":"8308_CR91","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.nbd.2008.10.003","volume":"35","author":"R Craig-Schapiro","year":"2009","unstructured":"Craig-Schapiro R, Fagan AM, Holtzman DM (2009) Biomarkers of Alzheimer\u2019s disease. Neurobiol Dis 35:128\u2013140. doi: 10.1016\/j.nbd.2008.10.003","journal-title":"Neurobiol Dis"},{"key":"8308_CR92","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1001\/archgenpsychiatry.2011.155","volume":"69","author":"P Buchhave","year":"2012","unstructured":"Buchhave P, Minthon L, Zetterberg H, Wallin AK, Blennow K, Hansson O (2012) Cerebrospinal fluid levels of \u03b2-amyloid 1-42, but not of tau, are fully changed already 5\u201310 Years before the onset of Alzheimer dementia. Arch Gen Psychiat 69:98\u2013106. doi: 10.1001\/archgenpsychiatry.2011.155","journal-title":"Arch Gen Psychiat"},{"key":"8308_CR93","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1016\/j.jalz.2014.07.037","volume":"10","author":"J Fortea","year":"2014","unstructured":"Fortea J, Benejam B, Alcolea D et al (2014) Core Alzheimer\u2019s disease CSF biomarkers in Down syndrome. Alzheimers Dement 10:882. doi: 10.1016\/j.jalz.2014.07.037","journal-title":"Alzheimers Dement"},{"key":"8308_CR94","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1159\/000358800","volume":"14","author":"E Portelius","year":"2014","unstructured":"Portelius E, Soininen H, Andreasson U et al (2014) Exploring Alzheimer molecular pathology in Down\u2019s syndrome cerebrospinal fluid. Neurodegener Dis 14:98\u2013106. doi: 10.1159\/000358800","journal-title":"Neurodegener Dis"},{"key":"8308_CR95","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1007\/s10519-006-9047-x","volume":"36","author":"SJ Teipel","year":"2005","unstructured":"Teipel SJ, Hampel H (2005) Neuroanatomy of Down syndrome in vivo: a model of preclinical Alzheimer\u2019s disease. Behav Genet 36:405\u2013415. doi: 10.1007\/s10519-006-9047-x","journal-title":"Behav Genet"},{"key":"8308_CR96","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1017\/S0033291708004054","volume":"39","author":"F Beacher","year":"2009","unstructured":"Beacher F, Daly E, Simmons A, Prasher V, Morris R, Robinson C, Lovestone S, Murphy K, Muprhy DG (2009) Alzheimer\u2019s disease and Down\u2019s syndrome: an in vivo MRI study. Psychol Med 39:675\u2013684. doi: 10.1017\/S0033291708004054","journal-title":"Psychol Med"},{"key":"8308_CR97","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1017\/S0033291709990985","volume":"40","author":"F Beacher","year":"2010","unstructured":"Beacher F, Daly E, Simmons A, Prasher V, Morris R, Robinson C, Lovestone S, Murphy K, Muprhy DG (2010) Brain anatomy and ageing in non-demented adults with Down\u2019s syndrome: an in vivo MRI study. Psychol Med 40:611\u2013619. doi: 10.1017\/S0033291709990985","journal-title":"Psychol Med"},{"key":"8308_CR98","doi-asserted-by":"publisher","first-page":"2556","DOI":"10.1093\/brain\/awu173","volume":"137","author":"SL Hartley","year":"2014","unstructured":"Hartley SL (2014) Cognitive functioning in relation to brain amyloid-\u03b2 in healthy adults with Down syndrome. Brain 137:2556\u20132563. doi: 10.1093\/brain\/awu173","journal-title":"Brain"},{"key":"8308_CR99","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1002\/ana.20009","volume":"55","author":"WE Klunk","year":"2004","unstructured":"Klunk WE, Engler H, Nordberg A et al (2004) Imaging brain amyloid in Alzheimer\u2019s disease with Pittsburgh Compound-B. Ann Neurol 55:306\u2013319. doi: 10.1002\/ana.20009","journal-title":"Ann Neurol"},{"key":"8308_CR100","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1016\/j.jalz.2015.07.490","volume":"12","author":"T Annus","year":"2015","unstructured":"Annus T, Wilson LR, Hong YT et al (2015) The pattern of amyloid accumulation in the brains of adults with Down syndrome. Alzheimer\u2019s Dement 12:538\u2013545. doi: 10.1016\/j.jalz.2015.07.490","journal-title":"Alzheimer\u2019s Dement"},{"key":"8308_CR101","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1016\/j.neuroimage.2007.09.064","volume":"39","author":"RJ Haier","year":"2008","unstructured":"Haier RJ, Head K, Head E, Lott IT (2008) Neuroimaging of individuals with Down\u2019s syndrome at-risk for dementia: evidence for possible compensatory events. Neuroimage 39:1324\u20131332. doi: 10.1016\/j.neuroimage.2007.09.064","journal-title":"Neuroimage"},{"key":"8308_CR102","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1016\/j.jalz.2015.01.006","volume":"11","author":"MN Sabbagh","year":"2015","unstructured":"Sabbagh MN (2015) Florbetapir PET, FDG PET, and MRI in Down syndrome individuals with and without Alzheimer\u2019s dementia. Alzheimers Dement 11:994\u20131004. doi: 10.1016\/j.jalz.2015.01.006","journal-title":"Alzheimers Dement"},{"key":"8308_CR103","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1177\/155005940904000211","volume":"40","author":"V Jelic","year":"2009","unstructured":"Jelic V, Kowalski JE (2009) Evidence-based evaluation of diagnostic accuracy of resting EEG in dementia and mild cognitive impairment. Clin EEG Neurosci 40:129\u2013142. doi: 10.1177\/155005940904000211","journal-title":"Clin EEG Neurosci"},{"key":"8308_CR104","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.jalz.2007.10.008","volume":"4","author":"CE Jackson","year":"2008","unstructured":"Jackson CE, Snyder PJ (2008) Electroencephalography and event-related potentials as biomarkers of mild cognitive impairment and mild Alzheimer\u2019s disease. Alzheimer\u2019s Dement 4:137\u2013143. doi: 10.1016\/j.jalz.2007.10.008","journal-title":"Alzheimer\u2019s Dement"},{"key":"8308_CR105","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/0306-4522(93)90284-M","volume":"53","author":"H Soininem","year":"1993","unstructured":"Soininem H, Partanen J, Jousmaki V, Helkala EL, Vanhanen M, Majuri S, Kaski M, Hartikainen P, Riekkinen P (1993) Age-related cognitive decline and electroencephalogram slowing in Down\u2019s syndrome as a model of Alzheimer\u2019s disease. Neuroscience 53:57\u201363. doi: 10.1016\/0306-4522(93)90284-M","journal-title":"Neuroscience"},{"key":"8308_CR106","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1016\/j.braindev.2004.07.008","volume":"27","author":"M Menendez","year":"2005","unstructured":"Menendez M (2005) Down syndrome, Alzheimer\u2019s disease and seizures. Brain Dev jpn 27:246\u2013252. doi: 10.1016\/j.braindev.2004.07.008","journal-title":"Brain Dev jpn"},{"key":"8308_CR107","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1159\/000438857","volume":"5","author":"LC Salem","year":"2015","unstructured":"Salem LC, Sabers A, Kjaer TW et al (2015) Quantitative electroencephalography as a diagnostic tool for Alzheimer\u2019s dementia in adults with down syndrome. Dement Geriatr Cogn 5:404\u2013413. doi: 10.1159\/000438857","journal-title":"Dement Geriatr Cogn"},{"key":"8308_CR108","doi-asserted-by":"publisher","first-page":"3043","DOI":"10.1167\/iovs.13-13629","volume":"55","author":"JM Larrosa","year":"2014","unstructured":"Larrosa JM, Garcia-Martin E, Bamboo MP, Pinilla J, Polo V, Otin S, Satue M, Herrero R, Pablo LE (2014) Potential new diagnostic tool for Alzheimer\u2019s disease using a linear discriminant function for fourier domain optical coherence tomography. Invest Ophthalmol Vis Sci 55:3043\u20133051. doi: 10.1167\/iovs.13-13629","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"8308_CR109","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1097\/01.wno.0000204645.56873.26","volume":"26","author":"PK Iseri","year":"2006","unstructured":"Iseri PK, Altinas O, Tokay T, Yuksel N (2006) Relationship between cognitive impairment and retinal morphological and visual functional abnormalities in Alzheimer disease. J Neuro Ophthalmol 26:18\u201324. doi: 10.1097\/01.wno.0000204645.56873.26","journal-title":"J Neuro Ophthalmol"},{"key":"8308_CR110","doi-asserted-by":"publisher","first-page":"2285","DOI":"10.1167\/iovs.06-1029","volume":"48","author":"F Berisha","year":"2007","unstructured":"Berisha F et al (2007) Retinal abnormalities in early Alzheimer\u2019s disease. Invest Ophthalmol Vis Sci 48:2285\u20132289. doi: 10.1167\/iovs.06-1029","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"8308_CR111","doi-asserted-by":"publisher","DOI":"10.1111\/j.1755-3768.2011.2262.x","author":"R Kromer","year":"2014","unstructured":"Kromer R et al (2014) Detection of retinal nerve fiber layer defects in Alzheimer\u2019s disease using SD-OCT. Front Psychiatry. doi: 10.1111\/j.1755-3768.2011.2262.x","journal-title":"Front Psychiatry"},{"key":"8308_CR112","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.neulet.2007.02.090","volume":"420","author":"C Paquet","year":"2007","unstructured":"Paquet C et al (2007) Abnormal retinal thickness in patients with mild cognitive impairment and Alzheimer\u2019s disease. Neurosci Lett 420:97\u201399. doi: 10.1016\/j.neulet.2007.02.090","journal-title":"Neurosci Lett"},{"key":"8308_CR113","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1016\/j.clineuro.2011.02.014","volume":"113","author":"A Kesler","year":"2011","unstructured":"Kesler A et al (2011) Retinal thickness in patients with mild cognitive impairment and Alzheimer\u2019s disease. Clin Neurol Neurosurg 113:523\u2013526. doi: 10.1016\/j.clineuro.2011.02.014","journal-title":"Clin Neurol Neurosurg"},{"key":"8308_CR114","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0010659","author":"JA Moncaster","year":"2010","unstructured":"Moncaster JA, Pineda R, Moir RD et al (2010) Alzheimer\u2019s disease amyloid-\u03b2 links lens and brain pathology in Down syndrome. PLoS One. doi: 10.1371\/journal.pone.0010659","journal-title":"PLoS One"},{"key":"8308_CR115","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.1016\/S0140-6736(03)12981-9","volume":"361","author":"LE Goldstein","year":"2003","unstructured":"Goldstein LE, Muffat JA, Cherny RA et al (2003) Cytosolic beta-amyloid deposition and supranuclear cataracts in lenses from people with Alzheimer\u2019s disease. Lancet 361:1258\u20131265. doi: 10.1016\/S0140-6736(03)12981-9","journal-title":"Lancet"},{"key":"8308_CR116","doi-asserted-by":"publisher","first-page":"e1000097","DOI":"10.1371\/journal.pmed1000097","volume":"6","author":"D Moher","year":"2009","unstructured":"Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009) Preferred Reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 6:e1000097. doi: 10.1371\/journal.pmed1000097","journal-title":"PLoS Med"}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-016-8308-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00415-016-8308-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-016-8308-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,14]],"date-time":"2019-09-14T19:21:29Z","timestamp":1568488889000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00415-016-8308-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,10,24]]},"references-count":116,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2017,4]]}},"alternative-id":["8308"],"URL":"https:\/\/doi.org\/10.1007\/s00415-016-8308-8","relation":{},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"value":"0340-5354","type":"print"},{"value":"1432-1459","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,10,24]]}}}